Colossal Biosciences Stock: Unlocking the Future of De-Extinction

Colossal Biosciences is a pioneering biotech company that's making headlines with its ambitious plans to bring back extinct species.

De-extinction, as a concept, is not new, but Colossal Biosciences is taking it to the next level with its cutting-edge technology and innovative approach.

The company has already made significant progress in this field, with its first project being the woolly mammoth, a species that went extinct thousands of years ago.

Colossal Biosciences aims to revive the woolly mammoth through a process called nuclear transfer, which involves transferring the nucleus of a mammoth cell into a more closely related elephant cell.

For another approach, see: Pacific Biosciences

Colossal Biosciences has achieved a valuation of $10.2 billion, making it a "decacorn" company.

This valuation is a result of a $200 million Series C funding round in January 2025, which is a significant increase from its previous valuation of $1.45 billion two years prior.

The company has raised over $400 million in total since its founding in 2021, demonstrating strong investor confidence.

Colossal Biosciences generates revenue through multiple channels, including technology licensing, government partnerships, and successful spin-offs.

Some of its notable spin-offs include Form Bio, which raised $35 million, and Breaking, which received $10.5 million in seed funding.

The company employs 170 scientists across its facilities in Dallas, Boston, and Melbourne, and sponsors over 40 postdoctoral researchers globally.

It also has a 95+ member scientific advisory board, which supports its R&D infrastructure and multiple concurrent projects in de-extinction, conservation, and biotechnology.

Here are some of the key partnerships and collaborations that Colossal Biosciences has established:

These partnerships provide both operational leverage and market validation for the company.

Colossal Biosciences aims to complete its major de-extinction projects by 2028 and beyond, but it's mitigating the investment horizon uncertainty through revenue-generating spin-offs and near-term commercial applications.

Colossal Biosciences has secured $435 million in funding, with a $10.2 billion valuation, making it Texas's first decacorn.

This substantial backing from sophisticated investors validates their technology and business approach. The company's revenue model is sophisticated, encompassing technology licensing agreements, strategic government partnerships, and anticipated biodiversity credits.

These multiple revenue streams help mitigate investment risks and demonstrate the company's financial strength.

Colossal Biosciences has secured $435 million in funding with a $10.2 billion valuation, making it Texas's first decacorn.

This impressive financial strength demonstrates regional market validation and impressive financial strength.

Their revenue model encompasses technology licensing agreements, strategic government partnerships, and anticipated biodiversity credits, creating multiple revenue streams while mitigating investment risks.

This sophisticated approach has attracted sophisticated investors, validating both their technology and business approach.

Colossal's revenue streams extend well beyond de-extinction research, generating revenue from biotech companies and research institutions through licensing its advanced genetic engineering tools.

Government partnerships in conservation create additional revenue channels, while future plans include entering the biodiversity credits market once extinct species are successfully reintroduced.

The company's success in launching spin-off ventures demonstrates its business acumen, with Form Bio securing $35 million in funding and Breaking raising $10.5 million in seed funding.

Colossal continues to expand with its recent $200 million funding round in January 2025, balancing progress on signature projects like the woolly mammoth and Tasmanian tiger resurrections with launching new ventures.

The company's growth strategy includes plans for three additional businesses, notably exploring artificial womb technology with applications in fertility treatment.

Here's an interesting read: Virtu Financial Stock

Colossal Biosciences is a privately held company, and its shares are not available for purchase on public exchanges. This means you can't just buy their stock on a public market like you would with other well-known companies.

Investors can still get in on the action, but they'll need to go through a pre-IPO broker like TSG Capital Advisors to make a purchase.

To buy stock, you can only do so via pre-IPO brokers and private market marketplaces.

Colossal Biosciences stock is not directly available to the public, so you'll need to work with a pre-IPO broker to learn more about investing.

Pre-IPO brokers, like TSG Capital Advisors, can provide information on the stock price, latest news about going public, and ways to invest indirectly.

Accredited investors can use pre-IPO brokers to explore investment options, including pooled investment vehicles managed by TSG Invest fund managers.

These vehicles offer a way to invest in Colossal Biosciences indirectly, providing a more accessible entry point for some investors.

If this caught your attention, see: So Stock

Colossal Biosciences is making rapid strides in technological advancements, particularly in the field of biotechnology. Their AI-powered platform, Form Bio, has revolutionized scientific R&D by enabling faster drug discovery and development.

Their advanced protein manufacturing methods, showcased in Breaking Bio, promise to revolutionize the production of lab-grown meat and other bioengineered products. This technology has already gained rapid market adoption and independent success.

Genetic engineering tools developed by Colossal enable precise genome modification, while advanced AI algorithms process complex biological data. Their expertise in embryology and stem cell research drives breakthroughs in cellular reprogramming and early development.

The company has made significant breakthroughs in genome editing, stem cell generation, and embryology. They have successfully generated the first de novo assembled mammoth genome and engineered elephant stem cells.

Colossal's technological capabilities span multiple cutting-edge fields, including genetic engineering, AI, embryology, and conservation biology. Their work extends into conservation, developing innovative solutions for species protection and ecosystem restoration.

If this caught your attention, see: Meta Ai Stocks

Investing in Colossal Biosciences requires accredited investor status, which means you'll need to have a certain level of wealth or income to qualify.

You can invest in Colossal Biosciences stock directly through pre-IPO marketplaces, but this option is typically reserved for accredited investors.

Opportunities to invest in Colossal Biosciences stock have become more frequent and plentiful thanks to its Series C funding round.

Accredited investors can find opportunities to invest in Colossal Biosciences stock on pre-IPO investing platforms, but most investors will need to wait until it becomes a public company.

Colossal Biosciences is likely a long way from going public, but if it does, retail IPO investors can find opportunities to buy stock during the IPO.

Investing in Colossal Biosciences through an ETF or mutual fund is often not possible, as private investment opportunities are generally not available via these channels.

However, if you can invest in Colossal Biosciences through an ETF or mutual fund, you won't have the option to purchase Colossal Biosciences stock directly, and you'll have no control over share management.

Take a look at this: A Growth Stock Mutual Fund Has Stocks That Are

You can explore options for buying Colossal Biosciences stock directly or alternative ways to invest in Colossal Biosciences by contacting TSG Invest today.

Retail investors can participate in the Colossal Biosciences IPO through a broker, but this is likely years away and often reserved for Wall Street's best customers.

TradeStation and Robinhood are online brokers that give customers free access to IPOs, even with low account balances, making it more attainable for investors to participate in the IPO.

A fresh viewpoint: Stock Market Investor

Colossal Biosciences is still a private company, which means it doesn't have a publicly traded stock price.

The company's valuation is $10.2 billion, based on a Series C funding round that raised $200 million in January 2025.

The Series C round priced the company's shares at about $25 per share, giving us a reliable price point at this time.

The company's valuation was estimated at $1.5 billion in January 2023, after a Series B funding round.

Colossal Biosciences doesn't have a publicly traded stock price yet, as the company is still private.

The Series C round priced shares at about $25 per share in January 2025, giving us the most reliable price point available.

This means if you're looking to invest in Colossal Biosciences, you'll need to wait until they go public or consider alternative investment options.

Colossal Biosciences has achieved a valuation of $10.2 billion based on the January 2025 Series C funding round that raised $200 million.

The company's valuation has increased significantly from the estimated $1.5 billion valuation in the January 2023 Series B round.

With the latest funding, Colossal Biosciences has become the first company founded and headquartered in Texas to become a 'decacorn', a privately held company with a valuation of more than $10 billion.

The company's valuation is a testament to the investor community's enthusiasm for its end-to-end de-extinction toolkit and its potential to revolutionize the field of genetic engineering.

Colossal Biosciences is a venture-backed biotech startup that has raised more than $400 million in private funding.

The company was founded in September 2021 by software entrepreneur Ben Lamm and geneticist-serial biotech entrepreneur George Church, Ph.D.

Colossal Biosciences has achieved a valuation of $10.2 billion after its latest Series C financing, making it the first company founded and headquartered in Texas to become a 'decacorn', or a privately held company with a valuation of more than $10 billion.

Colossal's investors include a diverse group of venture capital firms, including TWG Global, Tony Robbins, and USIT.

Colossal Biosciences has reached a $10 billion valuation, making it the first startup in Texas to achieve this milestone.

The company is on a mission to resurrect the woolly mammoth, a goal that's being driven by its genetic engineering technology.

Colossal Biosciences was founded in September 2021 by Ben Lamm and George Church, a Harvard and MIT professor.

The company has developed genomes for the woolly mammoth, as well as the dodo bird and the thylacine, a dog-like carnivorous marsupial with stripes.

Colossal has also developed an artificial uterus device to culture fertilized single-cell marsupial embryos.

The company's three active de-extinction projects include the woolly mammoth, the dodo bird, and the thylacine.

Ben Lamm, the CEO and co-founder of Colossal Biosciences, believes that the company's technology can help turn "science fiction into science fact".

Colossal has received $435 million in funding since its launch, with the latest round being $200 million in Series C financing from TWG Global.

This funding will help the company grow its team, develop new technology, and expand its de-extinction species list.

We're a company that's been around for 10 years, founded by a team of passionate individuals who wanted to make a difference in the world.

Our mission is to provide innovative solutions that make life easier and more enjoyable for our customers. We've been doing this by developing products that are not only functional but also sustainable and environmentally friendly.

We have a strong commitment to community involvement and have partnered with several local organizations to support their causes. This includes donating a portion of our profits to help fund their initiatives.

We're a company that values diversity and inclusion, with a team that reflects the diversity of the communities we serve. This diversity has helped us to stay innovative and bring new ideas to the table.

Our products are designed to be user-friendly and accessible to everyone, regardless of age or ability. We've made sure that our products meet the highest standards of accessibility and usability.

Colossal Biosciences is a venture-backed biotech startup that has raised over $400 million in private funding. This significant investment has helped the company grow and develop its innovative technologies.

The latest funding round, a Series C, was announced in January 2025 and was led by TWG Global. This notable investment demonstrates the company's potential for growth and success.

A number of venture capital investors have also contributed to Colossal Biosciences, including Tony Robbins and several other prominent firms.

Colossal Biosciences is poised for significant growth with its diversified approach to de-extinction and conservation biology. The company has secured a $200 million Series C funding round, valuing it at $10.2 billion.

Their innovative spin-offs, such as Form Bio and Breaking, are already creating value and have raised substantial funding. Form Bio has raised over $35 million, while Breaking secured $10.5 million in seed funding.

Colossal's partnerships with 48 conservation organizations worldwide will lead to comprehensive toolkits for species preservation. This collaboration will have a lasting impact on conservation efforts.

By 2028, Colossal aims to complete its ambitious de-extinction projects, which will revolutionize the field of conservation biology. The company's strategic positioning at the intersection of biotechnology, conservation, and artificial intelligence presents vast opportunities.

Their artificial womb technology, while initially intended for de-extinction, also shows promise in fertility applications. This dual-purpose technology could lead to breakthroughs in human fertility treatments.

Colossal is pioneering a novel approach to conservation funding through biodiversity credits, similar to carbon credits. This innovative financing model could become a game-changer for conservation efforts worldwide.

Investing in Colossal Biosciences is a high-risk, high-reward proposition. The company is a pioneer in de-extinction and synthetic biology, which means it's competing with established biotech companies and other genetic engineering startups for market share.

Colossal Biosciences is still in its early stages, and its current unprofitability is a major concern. The company's valuation is based on significant future breakthroughs in biotechnology, which is a rapidly evolving sector.

Regulatory challenges around genetic engineering are a significant risk, and so are the ethical considerations that come with it. These risks could have financial and reputational impacts on the company.

Investors should be aware that Colossal Biosciences has substantial investments in genetic technologies, which adds to the overall risk.